Does EVEROLIMUS Cause Focal segmental glomerulosclerosis? 25 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 25 reports of Focal segmental glomerulosclerosis have been filed in association with EVEROLIMUS (EVEROLIMUS). This represents 0.1% of all adverse event reports for EVEROLIMUS.
25
Reports of Focal segmental glomerulosclerosis with EVEROLIMUS
0.1%
of all EVEROLIMUS reports
0
Deaths
13
Hospitalizations
How Dangerous Is Focal segmental glomerulosclerosis From EVEROLIMUS?
Of the 25 reports, 13 (52.0%) required hospitalization.
Is Focal segmental glomerulosclerosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVEROLIMUS. However, 25 reports have been filed with the FAERS database.
What Other Side Effects Does EVEROLIMUS Cause?
Death (5,090)
Malignant neoplasm progression (3,789)
Diarrhoea (3,061)
Fatigue (2,946)
Stomatitis (2,692)
Nausea (2,079)
Dyspnoea (1,925)
Drug ineffective (1,837)
Pyrexia (1,664)
Decreased appetite (1,633)
What Other Drugs Cause Focal segmental glomerulosclerosis?
TACROLIMUS (339)
MYCOPHENOLATE MOFETIL (181)
PREDNISONE (173)
CYCLOSPORINE (96)
METHYLPREDNISOLONE (81)
PREDNISOLONE (73)
RITUXIMAB (73)
BASILIXIMAB (67)
OMEPRAZOLE (60)
LANSOPRAZOLE (55)
Which EVEROLIMUS Alternatives Have Lower Focal segmental glomerulosclerosis Risk?
EVEROLIMUS vs EVOLOCUMAB
EVEROLIMUS vs EXELON
EVEROLIMUS vs EXEMESTANE
EVEROLIMUS vs EXENATIDE
EVEROLIMUS vs EXFORGE